Payment overview · 2025
General Payments
$48.28
3 reported records · 2 companies
Healthcare provider profile · identity verified
Matthew Patrick Jackson, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWPORT, AR · NPI 1083689855
Verified facts
What the public records show
CMS Open Payments records show Matthew Patrick Jackson, MD received $48.28 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 71.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.40 | 71.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.88 | 28.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $48.28 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 745 | 187 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 528 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 429 | 105 |
| Omeprazole | Omeprazole | 413 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 81 |
| Potassium Chloride | Potassium Chloride | 391 | 77 |
| Lisinopril | Lisinopril | 375 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 365 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 80 |
| Duloxetine Hcl | Duloxetine Hcl | 306 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 62 |
| Furosemide | Furosemide | 291 | 78 |
| Gabapentin | Gabapentin | 291 | 65 |
| Metformin Hcl | Metformin Hcl | 287 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 67 |
| Meloxicam | Meloxicam | 252 | 62 |
| Pregabalin | Pregabalin | 241 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 51 |
| Tramadol Hcl | Tramadol Hcl | 218 | 47 |
| Lorazepam | Lorazepam | 215 | 35 |
| Eliquis | Apixaban | 214 | 33 |
| Losartan Potassium | Losartan Potassium | 200 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 195 | 40 |
| Carvedilol | Carvedilol | 184 | 38 |
| Trazodone Hcl | Trazodone Hcl | 184 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 25 |
| Celecoxib | Celecoxib | 166 | 32 |
| Metformin Hcl Er | Metformin Hcl | 160 | 32 |
| Alprazolam | Alprazolam | 158 | 34 |
| Glipizide | Glipizide | 153 | 32 |
| Sertraline Hcl | Sertraline Hcl | 149 | 38 |
| Clonazepam | Clonazepam | 147 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 143 | 26 |
| Famotidine | Famotidine | 140 | 34 |
| Ozempic | Semaglutide | 138 | 26 |
| Montelukast Sodium | Montelukast Sodium | 137 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 30 |
| Allopurinol | Allopurinol | 134 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 28 |
| Donepezil Hcl | Donepezil Hcl | 124 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 110 | 19 |
| Jardiance | Empagliflozin | 106 | 19 |
| Clonidine Hcl | Clonidine Hcl | 105 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 104 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 15 |
| Spironolactone | Spironolactone | 98 | 21 |
| Nifedipine Er | Nifedipine | 97 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 84 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 68 |
| Ondansetron Odt | Ondansetron | 83 | 27 |
| Prednisone | Prednisone | 81 | 60 |
| Aripiprazole | Aripiprazole | 78 | 15 |
| Mirtazapine | Mirtazapine | 76 | 19 |
| Simvastatin | Simvastatin | 76 | 18 |
| Topiramate | Topiramate | 73 | 14 |
| Azelastine Hcl | Azelastine Hcl | 69 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 20 |
| Mupirocin | Mupirocin | 65 | 50 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 64 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | 14 |
| Methocarbamol | Methocarbamol | 62 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 13 |
| Cephalexin | Cephalexin | 59 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 31 |
| Atenolol | Atenolol | 53 | 12 |
| Lamotrigine | Lamotrigine | 53 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 39 |
| Eszopiclone | Eszopiclone | 51 | 11 |
| Estradiol | Estradiol | 49 | 12 |
| Ezetimibe | Ezetimibe | 49 | 16 |
| Ibuprofen | Ibuprofen | 48 | 13 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 40 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Nystatin | Nystatin | 41 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | 13 |
| Buspirone Hcl | Buspirone Hcl | 38 | 14 |
| Fluconazole | Fluconazole | 38 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | 11 |
| Roflumilast | Roflumilast | 37 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Dutasteride | Dutasteride | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 30 |
| Meclizine Hcl | Meclizine Hcl | 35 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 15 |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Colchicine | Colchicine | 22 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 17 |
| Constulose | Lactulose | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 17 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Propafenone Hcl | Propafenone Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Asmanex | Mometasone Furoate | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.28 · 3 records | Novo Nordisk Inc | Ozempic, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error